Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Rejuvenate Biomed closes dosing follow-up in COPD muscle study, with data due before year-end

The Belgian-Dutch-listed developer says the final participant has completed RJx-01's placebo-controlled Phase 2 study, leaving results as the next test for a drug it also hopes to take into sarcopenia.

16 Nov 2026 · Rejuvenate Biomed NV · Company news

Rejuvenate Biomed NV said on 16 November 2026 that every participant in MINT-COPD, its Phase 2 trial of RJx-01, has now completed the study's last scheduled visit. The company reiterated that topline results are still expected by the end of 2026, leaving roughly six weeks for the data to emerge if that timetable holds.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →